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Summary.-Animals bearing metastatic fibrosarcomas were treated with cyclo-
phosphamide (CY) alone or in combination with flurbiprofen (FP), an inhibitor of
prostaglandin synthesis. FP did not affect local growth of fibrosarcomas, and the
incidence of distant metastases after resection of the "primary" implants was com-
parable in treated and control groups. Treatment with CY retarded growth of the
fibrosarcomas and reduced the proportion of animals which succumbed to metas-
tases, but this was not altered significantly by additional treatment with FP. FP did
not affect the survival of rats bearing a lymphoid leukaemia. The lifespan of animals
treated with CY was increased significantly, but the concomitant administration of
FP did not enhance this effect.
RAISED LEVELS of prostaglandins have
been found in in vitro cultures of tumour
cells (Jaffe et al., 1971; Levine et al., 1972;
Grinwich & Plescia, 1977) and in extracts
of experimental tumours (Sykes & Mad-
dox, 1972; Tashjian et al., 1973; Tan et al.,
1974; Humes & Strausser, 1974; Strausser
& Humes, 1975; Lynch et al., 1978) and
human neoplasms (Powles et al., 1976;
Bennett, 1979; Bennett et al., 1980). This
led to the idea that prostaglandins might
influence tumour growth and dissemina-
tion (Jaffe, 1974; Plescia et al., 1975;
Bennett et al., 1975; Dowsett et al., 1976;
Atkins et al., 1977). Although the manner
in which this may be achieved is not
clear, it has been proposed that increased
prostaglandin production by tumours
may subvert the immune response of the
host, or may aid bone destruction or
tissue breakdown, thereby facilitating
neoplastic invasion. Recently, it has been
reported that concomitant treatment with
inhibitors of prostaglandin synthesis im-
proved the therapeutic effect of cytotoxic
agents (Powles et al., 1978; Bennett et al.,
1979; Berstock et al., 1980).
We have sttudied the effect ofshort-term
administration of flurbiprofen (Froben,
The Boots Company Ltd), a potent
inhibitor of prostaglandin synthesis, alone
or in combination with cyclophosphamide,
on the growth and dissemination of 2
spontaneously metastatic rodent sarcomas
and a lymphoid leukaemia of rats.
MATERIALS AND METHODS
Animnals.-Male (220-270g) and female
(120-170g) Lister Hooded/Cbi rats and male
(20-30g) C57BL/Cbi mice over 10 weeks of
age were supplied by the Chester Beatty
Research Institute animal-breeding colony.
Rat tumours.-MC28, a methylcholanth-
rene-induced fibrosarcoma, was maintained
in syngeneic recipients by i.m. injection of a
mechanically prepared brei of tumour tissue.
Single-cell suspensions were prepared by
trypsinisation of the tumour. About 106
viable cells (as assessed by Trypan blue
exclusion) were injected s.c. into the flank
for the growth studies. This tumour is
weakly immunogenic and has a high incidence
of spontaneous metastases.
The lymphoid leukaemia HRL was of
spontaneous origin. Iv. injection of 106 cellsS. E. HECKFORD, S. A. ECCLES, T. J. POWLES AND P. ALEXANDER
kills syngeneic rats with widespread disease
within 3 weeks.
Mousetumours.-FS6MI, abenzo(a)pyrene-
induced fibrosarcoma was maintained by
serial i.m. passage in syngeneic C57BL/CBi
mice. It is weakly immunogenic, with a high
metastatic incidence (Mantovani, 1978).
Drugs.-Flurbiprofen (Froben, The Boots
Company Ltd, FP) is a potent non-steroidal
anti-inflammatory drug (NSAID) which in-
hibits the formation of prostaglandins from
precursor fatty acids. Animals were treated
thrice daily for 3 days at specified times
during tumour growth (Powles et at., 1978).
FP was administered s.c. in saline at doses of
7 mg/kg in rats and 5 mg/kg in mice.
Cyclophosphamide (Endoxana, CY) was
administered as a single i.p. injection of 10
or 100 mg/kg to mice and 80 mg/kg to rats,
on the second day of FP treatment (Powles
et al., 1978).
Subcutaneous tumour growth.-This was
assessed in situ from vernier caliper measure-
ments of the 2 greatest perpendicular
tumour diameters.
Tumour excision.-I.m. tumours were ex-
cised after 10-14 days ofgrowth by amputa-
tion of the whole limb. The animals were
observed for the development of metastatic
disease for 200 days after tumour resection.
Statistics.-Tumour growth was assessed
from plots of the mean diameter of the
tumours within a group +s.e. Animal
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survival data were analysed using Kaplan-
Meier lifetables and logrank P values as
defined by Peto et al. (1976) and their
significance assessed using x2 tests; a P of
<0 05 was considered significant.
RESULTS
Effectsofflurbiprofen andcyclophosphamide
Primary tumour growth.-Fig. 1 shows
that FP, given for 3 days, did not affect
the primary growth of rat sarcoma MC28;
the development of tumours in groups of
animals treated with 80 mg/kg CY was
delayed by 10 days, but this was not
changed significantly by the concomitant
administration of FP. Similarly, the
FS6M1 tumours of mice which had
received 10mg/kgCYalone, orin combina-
tion withFP, were ofsimilarsize (P> 0.05)
(Fig. 2); 100 mg/kg CY delayed tumour
growth (P< 0 01) but this was not affected
byadditionaltreatmentwithFP(P> 0-05).
Rats with the HRL leukaemia given CY
alone or in combination with FP survived
significantly longer (P< 0-001) than con-
trols or those receiving FP alone (Fig. 3).
However, animals receiving both CY and
FP became moribund at the same time as
those receiving CY alone (Fig. 3).
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FIG. 1.-Effect of cyclophosphamide (CY) ±flurbiprofen (FP) on the primary growth of MC28
fibrosarcoma following s.C. inoculation of 106 cells. * saline (controls); C) FP: 3 x 7 mg/kg daily,
Days 8-10; A CY: 80 mg/kg, Day 9; D FP+ CY. Mean of 4 tumours + s.e.
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FIG. 2.-The effect of cyclophosphamide (CY) ± flurbiprofen (FP) on the primary growth of FS6MI
fibrosarcoma following the s.c. inoculation of 106 cells. 0 saline (controls); 0 FP: 3 x 5 mg/kg
daily, Days 3-5; A CY: 0mg/kg, Day 6; O CY: (10 mg/kg)+FP; * CY: 100mg/kg, Day 6;
* CY: (100 mg/kg) +FP. Mean of 5 tumours +s.e.
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FIG. 3.-The effect of cyclophosphamide (CY) ±flurbiprofen (FP) on the survival of rats with HRL
leukaemia.
Controls Saline injections
FP 3 x 7 mg/kg daily, Days 1-3
CY 80 mg/kg, Day 2
The incidence of metastases.-The inci-
dence and distribution of metastases from
MC28 tumours are detailed in Fig. 4. A
high proportion of control animals and
those receiving FP alone died with
lymphatic and/or pulmonary metastases
within 62 days of tumour excision. The
administration of CY reduced the number
of animals succumbing to disseminated
disease (P< 0.05) but this was not altered
53S. E. HECKEORD, S. A. ECCLES, T. J. POWLES AND P. ALEXANDER
20 40 60 so 100 200
Days post tusour ec=ision
Fie. 4. Incidence and(l dlistribution of metastases after iesectioil of 1IC28 rat fibrosatecrrma in 12 rats.
Controls Saline injections
FP 3 x 7 mg/kg daily, Days 8-10
CY Cyclophosphamide, 80 mg/kg, Day 9
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Fie. 5.-Probability of survival after reseet ion of MC28 fibrosarcoma in 12 Irats. TIeatments received
during tumouir growth:
I. Controls
2. FP
3. CY
4. CY+FP
Saline injectioIns
3 x 7 mg/kg daily (Days 8-10)
80 mg/kg (Day 9)
by concomitant FP. The survival curves
shown in Fig. 5 lead to a similar conclusion.
Mice which had borne the FS6M1
fibrosarcoma and had received control
injections of saline died of pulmonary and
lymphatic metastases within 50 days of
tumour resection. This proportion was not
altered significantly by 10 mg/kg CY alone
or in combination with FP (P =0047).
The proportion ofanimals with pulmonary
or lymphatic metastases following treat-
ment with 100 mg/kg CY was significantly
lower (P < 001) than the proportion in
groups receiving saline or 10 mg/kg CY
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TABLE.-Incidenceanddistributionofmetastasesfromrn mousesarcomaFS6Mlafterresection
ofprimary tumour
Treatment
Saline
3-5 mg/kg FP (Days 3-
10 mg/kg CY (Day 6)
10 mg/kg CY+FP
100 mg/kg CY (Day 6)
100 mg/kg CY+FP
1
Probability
of
survival
0.8
0.6
0.4
0.2
N
23
-5) 19
24
24
21
19
Lung ± lymph r
A_
No.
23
17
20
17
7
5
Animals withi metastases
rndoe Visceral
0 No. %
100 0 0
89 2 11
83 4 17
11 3 12-5
33 4 19
26 2 11
Total
No. %
23 100
19 100
24 100
20 83
11 52
7 37
50 100 150 200
Time in days post tumour excision
FIG. 6. Probability of survival following resection of FS6MI sarcoma in mice. Treatmenits received
during tumour growth:
1. Controls
2. FP 3 x 5 mg/kg daily (Days 3-5)
3. CY 10 mg/kg (Day 6)
4. CY 1Omg/kg+FP
5. CY 100 mg/kg (Day 6)
6. CY 100 mg/kg+FP
alone (Table). Kidney and liver metastases
occurred in a few animals, but their low
incidence (Table) did not allow a valid
statistical appraisal.
The probability of survival was signifi-
cantly greater (P < 0.05) in animals treated
with 100 mg/kg CY (± FP) than those
which had received 10 mg/kg CY ( ± FP)
or saline (Table and Fig. 6). The survival
of FP-treated mice was slightly greater
than controls (P = 0 057) and although FP
tended to improve the probability of
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survival for mice treated with 10 mg/kg
(P= 0.08) or 100 mg/kg (P = 0.38) CY, this
was not significant at the 5% level.
DISCUSSION
The experiments reported above were
undertaken to investigate the effect of a
treatment combining the cytotoxic agent
cyclophosphamide (CY), and flurbiprofen
(FP), an inhibitor of prostaglandin syn-
thesis, on the growth and dissemination
of 3 rodent tumours. Previous reports in
the literature had indicated that FP
enhanced the therapeutic effect of an
alkylating agent against an ascitic rat
tumour (Powles et al., 1978) and of
radiation and cytotoxic agents against the
local growth and secondary spread of a
murine adenocarcinoma (Bennett et al.,
1979; Berstock et al., 1980).
The HRL rat leukaemia used in our
study disseminates via the blood stream,
and animals succumb to widespread
disease within 3 weeks. The progression of
this tumour was not affected by treatment
with FP for 3 days. The increased animal
survival time with CY was notsignificantly
affected by the concomitant administra-
tion of FP.
The fibrosarcomas chosen for this study
disseminate spontaneously via both lym-
phatic and haematogenous routes, and the
very low incidence of locally recurrent
tumours (< 50) allowed a clear assess-
ment ofthe effect of a particular treatment
on distant metastases (any animal with a
local regrowth of tumour at the excision
site was not included in the statistical
analysis). In summary, short-term treat-
ment with FP alone did not affect
primary growth of the fibrosarcomas; the
incidence of distant metastases following
resection of the tumours was also com-
parable to that in untreated controls,
though the probability of survival was
slightly greater for groups of mice re-
ceiving FP (P = 0 057). Treatment of mice
with FS6M1 fibrosarcoma with 10mg/kg
CY did not improve the probability of
survival (P> 0.05). High doses of CY
retarded growth of the fibrosarcomas and
reduced the proportion of animals which
succumbed to metastases (P < 0 05) and
although additional treatment with FP
tended to increase the probability of
survival in mice (P=0-08 for 10 mg/kg CY
and P=0 38 for 100 mg/kg CY this was
not significant at the 5% level.
Experiments in which anti-inflamma-
tory drugs (NSAID) alone have been
administered to tumour-bearing animals
have yielded disparate results: some
authors have recorded that such treatment
did not affect tumour growth (Sykes &
Maddox, 1972; Powles et al., 1978) whilst
others have found it inhibited (Tashjian
et al., 1973; Plescia et al., 1975; Hial et al.,
1976) and animal survival increased
(Strausser & Humes, 1975; Lynch et al.,
1978) particularly if treatment with the
NSAID was initiated at the same time as
tumour inoculation (Bennett et al., 1979;
Trevisani et al., 1980). As FP was admin-
istered for only a short period during
tumour growth in this study, further
experiments were performed in which FP
treatment was initiated the day oftumour
inoculation and continued daily until
resection; this protocol also failed to
affect the growth and dissemination ofthe
sarcomas, as reported elsewhere (Heck-
ford, 1980).
FP has been shown to inhibit prosta-
glandin formation at doses of 0 1-0 5 mg/
kg (Whittle et al., 1980) but over 3 days,
the high doses used in this study (5-7 mg/
kg) were well tolerated, with no evidence
of gastro-intestinal toxicity.
Theresults described above demonstrate
that, for small groups of animals, short-
term treatment with FP exerted a small
but statistically insignificant enhancement
of the therapeutic effect of CY against the
primary and secondary growth of 3 rodent
tumours. Reports of other experiments,
using different treatment protocols and
tumours of various histogenic origin, have
yielded some evidence of enhancement of
the therapeutic effect of cytotoxic drugs
by concomitant administration of
NSAIDs. Further experiments must be
undertaken, in order to identify any
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effects of anti-inflammatory drugs on
tumour growth and dissemination.
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